Share this article
LUND, Sweden, April 21, 2021 /PRNewswire/
Immunovia today announced an updated assessment of the total market size for familial/hereditary pancreatic cancer risk group in the US. New estimations show that 315,000 – 350,000 individuals have a familial/hereditary risk for pancreatic cancer and would qualify to be enrolled in pancreatic cancer surveillance programs.
Immunovia s bloodtest IMMray™ PanCan-d for early detection of pancreatic cancer is to be used for surveillance testing of high risk individuals. The recent blided validation study showed that IMMray™ PanCan-d and the tumor marker CA 19-9 detect stage I & II pancreatic cancer with 85% sensitivity and 98% specificity in familial/hereditary pancreatic cancer risk group.
(1)
LUND, Sweden, April 21, 2021 /PRNewswire/
Immunovia today announced an updated assessment of the total market size for familial/hereditary pancreatic cancer risk group in the US. New estimations show that 315,000 - 350,000 individuals have a familial/hereditary risk for pancreatic cancer and would qualify to be enrolled in pancreatic cancer surveillance programs.
Immunovia s bloodtest IMMray PanCan-d for early detection of pancreatic cancer is to be used for surveillance testing of high risk individuals. The recent blided validation study showed that IMMray PanCan-d and the tumor marker CA 19-9 detect stage I & II pancreatic cancer with 85% sensitivity and 98% specificity in familial/hereditary pancreatic cancer risk group.
Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year
Daiichi Sankyo UK, Limited
(hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies.
In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive.
Press release content from Business Wire. The AP news staff was not involved in its creation.
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
April 20, 2021 GMT
Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu ® (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies.
In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive. 1,2,3 The impact of the disease is significant, with breast cancer responsible for approximately 12,000 deaths per year. 1 There are an estimated 35,000 people living with metastatic breast
New recipients for the 2021 NCCN Foundation Young Investigator Awards announced
The National Comprehensive Cancer Network
® (NCCN
®) and the NCCN Foundation
® today announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards (YIA) Program. The honorees will receive up to $150,000 in funding, over two years, to advance important research on important issues in oncology. These early-career investigators from NCCN Member Institutions represent tomorrow s leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) managed the selection process and will provide guidance and oversight for the projects over the grant duration. NCCN is committed to improving the lives of people with cancer by supporting research that is novel, transparent, and meaningful, said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. The NCCN Foundation Young Investigator Awards Program exemplifies this objective by fostering emerging talent and exploring promising area